BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

89bio Inc.

Headquarters: San Francisco, CA, United States of America
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Rohan Palekar, MBA
Number Of Employees: 93
Enterprise Value: $416,462,274
PE Ratio: -2.38
Exchange/Ticker 1: NASDAQ:ETNB
Exchange/Ticker 2: N/A
Latest Market Cap: $1,194,148,992

BioCentury | Feb 19, 2025
Finance

China competition. Plus: FDA firings and biotech IPOs  

Why U.S. biotechs should embrace the challenge from China biotech
BioCentury | Feb 1, 2025
Finance

Metsera, Maze land on NASDAQ as IPO queue grows

BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
BioCentury | Jan 28, 2025
Product Development

Patience pays off for Akero in MASH

After a stumble in 2023, FGF21 agonist demonstrates fibrosis improvement in cirrhosis patients
BioCentury | Nov 15, 2024
Finance

Syncona building Slingshot incubator; Trace launches with $101M

BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Sep 17, 2024
Management Tracks

Peter Maag resigns as Kyverna CEO

Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more 
BioCentury | Aug 9, 2024
Management Tracks

A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element

Plus: Sarena becomes COO of 89bio
BioCentury | Mar 14, 2024
Regulation

Madrigal’s MASH drug is approved, now it’s time to build the market

FDA approves Rezdiffra as first MASH therapy
BioCentury | Mar 6, 2024
Product Development

Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks

Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood  
BioCentury | Feb 6, 2024
Product Development

Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more

Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
BioCentury | Oct 10, 2023
Product Development

Akero’s NASH readout spreads worries to others in class

Despite miss on fibrosis endpoint, biotech touts strong performance on disease resolution, says totality of data support Phase III start
Items per page:
1 - 10 of 39
Help Center
Username
Request a Demo
Request Training
Ask a Question